CSCI vs. PEPG, TPST, DTIL, CLNN, MDCX, ELEV, ANVS, CASI, ATHE, and SRZN
Should you be buying COSCIENS Biopharma stock or one of its competitors? The main competitors of COSCIENS Biopharma include PepGen (PEPG), Tempest Therapeutics (TPST), Precision BioSciences (DTIL), Clene (CLNN), Medicus Pharma (MDCX), Elevation Oncology (ELEV), Annovis Bio (ANVS), CASI Pharmaceuticals (CASI), Alterity Therapeutics (ATHE), and Surrozen (SRZN). These companies are all part of the "pharmaceutical products" industry.
COSCIENS Biopharma vs.
COSCIENS Biopharma (NASDAQ:CSCI) and PepGen (NASDAQ:PEPG) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, earnings, profitability, analyst recommendations, dividends, valuation, risk and community ranking.
PepGen has a net margin of 0.00% compared to COSCIENS Biopharma's net margin of -428.43%. PepGen's return on equity of -60.17% beat COSCIENS Biopharma's return on equity.
PepGen has a consensus price target of $10.33, suggesting a potential upside of 654.26%. Given PepGen's stronger consensus rating and higher possible upside, analysts plainly believe PepGen is more favorable than COSCIENS Biopharma.
COSCIENS Biopharma has higher revenue and earnings than PepGen. PepGen is trading at a lower price-to-earnings ratio than COSCIENS Biopharma, indicating that it is currently the more affordable of the two stocks.
0.7% of COSCIENS Biopharma shares are held by institutional investors. Comparatively, 58.0% of PepGen shares are held by institutional investors. 0.1% of COSCIENS Biopharma shares are held by insiders. Comparatively, 4.6% of PepGen shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
PepGen received 19 more outperform votes than COSCIENS Biopharma when rated by MarketBeat users.
COSCIENS Biopharma has a beta of 1.53, meaning that its share price is 53% more volatile than the S&P 500. Comparatively, PepGen has a beta of 1.53, meaning that its share price is 53% more volatile than the S&P 500.
In the previous week, COSCIENS Biopharma's average media sentiment score of 0.00 equaled PepGen'saverage media sentiment score.
Summary
PepGen beats COSCIENS Biopharma on 9 of the 13 factors compared between the two stocks.
Get COSCIENS Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for CSCI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
COSCIENS Biopharma Competitors List
Related Companies and Tools
This page (NASDAQ:CSCI) was last updated on 2/22/2025 by MarketBeat.com Staff
